Ophthalmology visionary Mark S. Blumenkranz, MD, MMS, to joi…
News
July, 11 2022 • Articles
Opus Genetics to Present at OIS Retina Innovation Summit 2022
Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Ben Yerxa, Ph.D., president and CEO of Opus, will present at the Ophthalmology Innovation Source (OIS) Retina Innovation Summit 2022 on Wednesday, July 13, 2022, in New York.
Dr. Yerxa will deliver a company overview as part of the Innovation Showcase to discuss Opus’ unique model of combining validated science and commitment to patient need with wholly owned programs in inherited retinal diseases. Dr. Yerxa will also highlight Opus’ lead AAV-based gene therapy programs being developed to address mutations in genes that cause different forms of Leber congenital amaurosis (LCA).
“We’re honored to be selected to participate in the OIS Innovation Showcase and highlight Opus’ patient-first, science-driven approach and pipeline of AAV-based gene therapy programs,” said Dr. Yerxa. “Opus’ mission is to build an engine to accelerate multiple rare genetic retinal disease therapeutics into the clinic and ultimately to the patients who need them. We look forward to providing an update on our LCA programs approaching clinical stage in the near-term, as well as our long-term approach to addressing additional genetic targets across the broad spectrum of inherited retinal diseases.”
The OIS Retina Innovation Summit brings together entrepreneurs, ophthalmic start-up companies, clinical thought leaders, industry executives and investment professionals for a day-long summit showcasing novel therapies in development for ophthalmic diseases and vision disorders. For more information, visit https://ois.net/ois-retina-innovation-summit-2022/.
About Opus Genetics
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Research Triangle Park, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.
Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
01/06/2023
The Retinal Degeneration Fund invests in a $78M Series B for Percei…
The investment supports the clinical development of two nove…
12/28/2022
Opus Genetics Announces Acquisition of the Rights to Two Gene Thera…
Opus to advance preclinical development programs for BEST1- …
12/01/2022
SparingVision's lead asset SPVN06 clears IND application in the US…
SparingVision set to advance into the clinic with breakthrou…
12/01/2022
Opus Genetics Receives FDA Clearance of IND Application for OPGx-00…
OPGx-001 is Opus’ first program to enter clinical evaluation…
11/10/2022
Foundation Launching its Largest Natural History Study to Date for…
Uni-Rare Study will improve clinical understanding of more I…
11/08/2022
Nacuity Pharmaceuticals Expands Board of Directors with Appointment…
Managing director of the Retinal Degeneration Fund joins boa…
11/08/2022
Atsena Therapeutics Expands Leadership Team with Appointment of Lis…
Biotech leader brings extensive experience in finance, busin…
10/12/2022
Ascidian Therapeutics Launches to Rewrite RNA
ATP incubated and built Ascidian with $50 million in Series …
10/03/2022
Atsena Therapeutics Announces Positive Results from Phase I/II Clin…
ATSN-101 demonstrated clinically meaningful improvements in …
09/27/2022
Opus Genetics Expands Board of Directors with Appointment of Global…
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE…
09/15/2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene…